Product Name
FANCL, siRNA
Full Product Name
FANCL siRNA (Human)
Product Synonym Names
PHF9; E3 ubiquitin-protein ligase FANCL; Fanconi anemia group L protein; Fanconi anemia-associated polypeptide of 43 kDa; FAAP43
Product Gene Name
FANCL sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9NW38
Specificity
FANCL siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human FANCL gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of FANCL sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
FANCL sirna
siRNA to inhibit FANCL expression using RNA interference
Applications Tested/Suitable for FANCL sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for FANCL. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001108108.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001114636.1
[Other Products]
UniProt Primary Accession #
Q9NW38
[Other Products]
UniProt Secondary Accession #
Q6GU60[Other Products]
UniProt Related Accession #
Q9NW38[Other Products]
Molecular Weight
43,430 Da
NCBI Official Full Name
E3 ubiquitin-protein ligase FANCL isoform 1
NCBI Official Synonym Full Names
Fanconi anemia, complementation group L
NCBI Official Symbol
FANCL??[Similar Products]
NCBI Official Synonym Symbols
POG; PHF9; FAAP43
??[Similar Products]
NCBI Protein Information
E3 ubiquitin-protein ligase FANCL
UniProt Protein Name
E3 ubiquitin-protein ligase FANCL
UniProt Synonym Protein Names
Fanconi anemia group L protein; Fanconi anemia-associated polypeptide of 43 kDa; FAAP43
Protein Family
E3 ubiquitin-protein ligase
UniProt Gene Name
FANCL??[Similar Products]
UniProt Synonym Gene Names
PHF9; FAAP43??[Similar Products]
UniProt Entry Name
FANCL_HUMAN
NCBI Summary for FANCL
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group L. Alternative splicing results in two transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008]
UniProt Comments for FANCL
FANCL: Ubiquitin ligase protein that mediates monoubiquitination of FANCD2, a key step in the DNA damage pathway. Also mediates monoubiquitination of FANCI. May stimulate the ubiquitin release from UBE2W. May be required for proper primordial germ cell proliferation in the embryonic stage, whereas it is probably not needed for spermatogonial proliferation after birth. Defects in FANCL are the cause of Fanconi anemia complementation group L (FANCL). FANCL is a disorder affecting all bone marrow elements and resulting in anemia, leukopenia and thrombopenia. It is associated with cardiac, renal and limb malformations, dermal pigmentary changes, and a predisposition to the development of malignancies. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage) and defective DNA repair. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: EC 6.3.2.-; EC 6.3.2.19; Ubiquitin ligase; Ubiquitin conjugating system; Ligase
Chromosomal Location of Human Ortholog: 2p16.1
Cellular Component: nucleoplasm; cytoplasm; nuclear envelope
Molecular Function: zinc ion binding; ubiquitin protein ligase binding; ubiquitin-protein ligase activity; ligase activity
Biological Process: protein monoubiquitination; gamete generation; DNA repair; response to DNA damage stimulus; regulation of cell proliferation
Disease: Fanconi Anemia, Complementation Group L; Tracheoesophageal Fistula With Or Without Esophageal Atresia
Research Articles on FANCL
1. a signal transduction pathway involved in self-renewal and survival of hematopoietic stem cells also functions to stabilize FANCL and suggesting that FANCL participates directly in support of stem cell function.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
